论文部分内容阅读
应用乳酸脱氢酶释放法对重组白介素２，粗制天然白介素２，重组肿瘤坏死因子和天然免疫活性肽等淋巴因子诱导人ＰＢＭＮＣ为ＬＡＫ细胞以及ＬＡＫ细胞对靶细胞（人外周血淋巴细胞，人食管癌１０９细胞株和人红白血病细胞株＿（５６２）的细胞毒作用分别于培养的第４ｄ和第７ｄ进行了检测。结果显示：①四个配伍组和一个重组白介素２组的多克隆ＬＡＫ细胞攻击溶解１０９细胞株和Ｋ＿（５６２）细胞株的水平波动子２８％和６６％之间，中位数为４７％，而对正常人外周血淋巴细胞均无细胞毒作用；②重组白介素２和粗制天然白介素２配伍培养ＬＡＫ细胞的增殖协力约高于重组白介素２和重组肿瘤坏死因子组，以及重组白介素２和免疫活性肽组增殖协力的３倍，③在诱导ＬＡＫ细胞的过程中其增殖量和其细胞毒活性可以不同步。建议临床上治疗晚期肿瘤病人除用ＬＡＫ细胞和重组白介素２外，首先选用天然白介素２。
Lactogen dehydrogenase release method of recombinant interleukin 2, crude natural interleukin 2, recombinant tumor necrosis factor and natural immune peptides and other lymphokines induce human PBMNC to LAK cells and LAK cells to target cells (human peripheral blood lymphocytes, human The cytotoxicity of esophageal 109 cell line and human erythroleukemia cell line (562) were detected on day 4 and day 7 respectively.The results showed that: (1) The polyclonal LAK of four compatibility groups and one recombinant interleukin 2 Cytotoxicity was observed in 28% and 66% of the 109 cells and K562 cell lines, respectively, with a median of 47%, but no cytotoxic effect on normal human peripheral blood lymphocytes. The proliferation of LAK cells co-cultured with crude natural interleukin 2 was about 3 times higher than that of recombinant interleukin 2 and recombinant tumor necrosis factor, and 3 times of that of recombinant interleukin 2 and immunocompetent peptides. ③ In the process of inducing LAK cells The amount of proliferation and its cytotoxic activity may not be synchronized Treatment of patients with advanced cancer bed except with LAK cells and recombinant interleukin-2, interleukin-natural first choice 2.